Bausch + Lomb Corporation (NYSE/TSX: BLCO) and its controlling shareholder, Bausch Health Companies Inc. (NYSE/TSX: BHC), announced on October 12, 2026, that Thomas J. Appio had been appointed interim chief executive officer of Bausch + Lomb, effective immediately, following the mutually agreed departure of Brent Saunders. Appio will retain his position as chief executive officer of Bausch Health while leading the global eye-care company, creating a dual leadership arrangement across two publicly traded businesses. The companies also disclosed that preliminary third-quarter results support an expected increase in their full-year 2026 adjusted earnings guidance, with additional financial details scheduled for October 28.
The announcement brings together two developments that investors will assess differently. The anticipated earnings improvement suggests that operating momentum remained favourable during the third quarter, building on Bausch + Lomb’s 9% reported revenue growth and stronger cash generation in the preceding quarter. Saunders’ departure, meanwhile, introduces uncertainty over executive succession and the continuity of a growth strategy developed during his tenure.
The ownership structure makes this more consequential than a conventional chief executive transition. Bausch Health owned approximately 87% of Bausch + Lomb’s outstanding shares as of August 2026, and the companies have been working within a broader, still-uncompleted separation framework following the eye-care business‘s 2022 initial public offering. Appio’s appointment brings the two businesses under the leadership of the same executive while their future ownership relationship remains a significant strategic consideration.
Why is Brent Saunders leaving Bausch + Lomb, and what changes under Thomas Appio?
Bausch + Lomb said Saunders and the company’s board of directors had mutually agreed that he would depart after serving as chief executive officer since 2023. The announcement did not provide a detailed reason for the change, identify a disagreement over strategy or disclose a timetable for appointing a permanent successor. As a result, the circumstances should not be interpreted as evidence of an operational dispute or a decision to abandon the company’s existing strategic plan.
Saunders returned to Bausch + Lomb during an important period in its development as a separately listed eye-care business. His tenure included portfolio expansion, investment in ophthalmic pharmaceuticals and surgical technologies, and a greater emphasis on operating efficiency and profitable growth. In his departure statement, Saunders characterised the company as having a clearer strategy, a stronger development pipeline and improved positioning for future growth.
Appio brings extensive experience within both businesses, having served as Bausch Health’s chief executive officer since May 2022. He joined Bausch + Lomb in 2010 as managing director for China and later became president of its international operations in 2016. His earlier career also included more than two decades with Schering-Plough, providing a background in pharmaceutical management and international commercial operations.
The appointment is not entirely unexpected from a governance perspective. Appio joined Bausch + Lomb’s board in August 2026 and subsequently became chairman, establishing a direct leadership connection before the October executive transition. The board cited his knowledge of the eye-care business, international experience and longstanding involvement with the organisation as reasons for selecting him to lead the company on an interim basis.
How much could Bausch + Lomb raise its 2026 earnings guidance after the third quarter?
The financial announcement is specific in one important respect: the expected improvement concerns adjusted EBITDA excluding acquired in-process research and development expenses, a non-GAAP profitability measure used by Bausch + Lomb. The company has not yet published a revised numerical range, and the preliminary announcement should not be interpreted as a confirmed increase in revenue guidance or reported net profit.
Under the guidance issued on July 29 and reaffirmed on August 6, Bausch + Lomb expected full-year 2026 revenue between $5.44 billion and $5.54 billion. It also projected adjusted EBITDA excluding acquired in-process research and development expenses of $1.025 billion to $1.075 billion. Those figures remain the latest published numerical benchmarks against which the anticipated upward revision can be assessed.
Bausch Health also expects to raise its full-year adjusted earnings outlook. Its July guidance projected consolidated 2026 revenue of $10.79 billion to $11.04 billion and consolidated adjusted EBITDA of $4.05 billion to $4.175 billion. Because the parent consolidates Bausch + Lomb’s financial results, the two companies’ earnings forecasts cannot be added together as independent amounts.
Management attributed the expected improvement to continued strong third-quarter business performance and anticipation of stronger results during the remainder of 2026. The figures are preliminary and unaudited, with normal quarter-end accounting and review procedures still to be completed. Investors will therefore need to examine the actual October 28 results before determining the size, sustainability and sources of the earnings improvement.
Another distinction concerns the profitability metric itself. Adjusted EBITDA excludes interest, taxes, depreciation, amortisation and several additional items, while the particular Bausch + Lomb measure also excludes acquired in-process research and development expenses. It can provide useful information about underlying operating trends, but it is not equivalent to cash flow, GAAP operating income or net earnings attributable to shareholders.
What do Bausch + Lomb’s second-quarter results reveal about its improving profitability?
The expectation of stronger third-quarter earnings follows an already improved second-quarter performance. Bausch + Lomb reported revenue of $1.394 billion for the three months ended June 30, 2026, compared with $1.278 billion a year earlier. Revenue increased 9% on a reported basis and approximately 8% at constant exchange rates, with growth recorded across all three operating segments.
The Vision Care business generated $784 million in quarterly revenue, increasing 4% from $753 million in the corresponding 2025 period. Growth was supported by daily silicone hydrogel contact lenses, Biotrue and ULTRA products, alongside over-the-counter dry eye treatments. This segment remains the company’s largest revenue contributor, making continued demand and effective product execution important to overall financial performance.
The Surgical business delivered stronger percentage growth, with revenue increasing 19% to $256 million from $216 million. Bausch + Lomb attributed the improvement primarily to its premium intraocular lens portfolio, while constant-currency segment growth reached approximately 16%. Demand for premium ophthalmic surgical products is commercially relevant because it can influence product mix and operating margins, although segment-level revenue growth alone does not establish higher profitability.
Pharmaceuticals revenue rose 15% to $354 million, supported by MIEBO and XIIDRA, as well as international prescription pharmaceutical sales. The two dry eye medicines provide an important link between the company’s commercial ophthalmology portfolio and its broader strategy of developing differentiated treatment options. Their contribution also illustrates why Bausch + Lomb’s financial performance cannot be evaluated solely through contact lenses or surgical equipment.
The profitability improvement was substantial. Second-quarter adjusted EBITDA excluding acquired in-process research and development expenses increased to $246 million from $192 million, a rise of approximately 28%. GAAP operating income reached $83 million, compared with an operating loss of $11 million a year earlier, while the net loss attributable to Bausch + Lomb narrowed to $14 million from $62 million.
Operating cash flow improved to $153 million from $35 million in the prior-year quarter. This improvement provides additional support for the company’s claim that operational efficiencies are contributing to financial progress, rather than the reported earnings improvement being visible only in adjusted measures. Nevertheless, the remaining GAAP net loss shows that stronger adjusted profitability has not yet translated into consistent bottom-line profitability.
Why does Thomas Appio’s dual leadership role matter for the Bausch Health separation?
The dual chief executive arrangement has particular significance because Bausch + Lomb remains controlled by Bausch Health despite having publicly traded shares on the New York Stock Exchange and Toronto Stock Exchange. The parent owned approximately 87% of the company’s outstanding shares when it announced board changes in August. Public investors therefore hold a minority economic interest in a business whose controlling shareholder has considerable influence over governance and strategic decisions.
Bausch Health originally announced plans to separate its eye-health business in August 2020, and Bausch + Lomb completed its initial public offering in 2022. The listing established a separately traded company but did not complete the broader separation because Bausch Health retained its controlling ownership position. The parent has continued evaluating potential routes to monetise or distribute its remaining interest.
Those alternatives have included selling some or all of the ownership stake, distributing shares to Bausch Health shareholders or pursuing a transaction involving the eye-care business. However, the company’s latest filings emphasise that a complete separation remains subject to financial, regulatory, shareholder and other conditions. No completion timetable or definitive transaction structure was established by the October 12 leadership announcement.
Appio’s appointment creates an unusual governance situation in which the same executive leads the controlling shareholder and the separately listed subsidiary. This arrangement may improve coordination between the two businesses, particularly when decisions involve capital allocation, financing or their future ownership relationship. At the same time, it increases the importance of board oversight and procedures addressing decisions where the interests of the parent and minority shareholders might differ.
The October announcement does not establish that the appointment signals an imminent sale, distribution or reversal of the separation strategy. It also does not indicate that Bausch + Lomb will cease operating as a separately listed company. Any material change to the ownership structure would require further corporate disclosures and, where applicable, the necessary approvals.
Could Bausch Health’s debt obligations influence the future of Bausch + Lomb?
The ownership discussion cannot be separated from Bausch Health’s financial structure. At June 30, 2026, the parent reported approximately $20.24 billion in consolidated debt principal obligations, including roughly $5.13 billion attributable to Bausch + Lomb’s own financing arrangements. The figures represent consolidated obligations across the businesses rather than debt owed exclusively by the parent outside its eye-care subsidiary.
Bausch Health has previously explained that completing a distribution of Bausch + Lomb shares is dependent in part on achieving targeted debt leverage ratios. Its filings also identify potential asset monetisation and financing transactions as options for managing debt obligations and future maturities. Consequently, the value and ownership of Bausch + Lomb remain strategically relevant to the wider group’s financial flexibility.
Appio’s leadership of both companies could simplify coordination over these financial priorities, but the potential advantages must be considered alongside the interests of minority Bausch + Lomb shareholders. A transaction designed to strengthen the parent’s balance sheet would still need to account for the financial and governance consequences for the eye-care company. The October announcement contains no new debt restructuring agreement or commitment to dispose of shares.
Improving profitability at both companies may strengthen their financial positions, but higher adjusted EBITDA does not directly eliminate debt. Cash generation, capital expenditure, interest payments and available refinancing options will remain important in assessing financial flexibility. Those measures will become particularly relevant if the expected earnings upgrades prompt renewed attention to the unfinished separation.
How might the CEO transition affect Bausch + Lomb’s ophthalmology and surgical growth strategy?
Bausch + Lomb’s strategy extends across contact lenses, surgical equipment, intraocular lenses, prescription eye medicines and consumer eye-health products. Its broad portfolio provides multiple opportunities for growth, but also requires disciplined investment decisions across businesses with different regulatory pathways, manufacturing requirements and customer groups. A change in chief executive could influence the pace or prioritisation of those investments, although no revised operating strategy has been announced.
At its November 2025 investor day, Bausch + Lomb established a three-year financial framework targeting compound annual revenue growth of 5% to 7% at constant currency through 2028. Management also targeted an adjusted EBITDA margin, excluding acquired in-process research and development expenses, of approximately 23% in 2028. These were management objectives rather than guaranteed outcomes, and the October leadership change does not itself confirm an alteration to the targets.
The second-quarter results provide evidence of progress towards stronger margins. Adjusted EBITDA excluding acquired in-process research and development expenses represented approximately 17.6% of quarterly revenue, compared with roughly 15.0% in the previous year’s second quarter. The calculation indicates improved operating leverage, although a single quarter’s margin should not be treated as a direct forecast of the full-year or 2028 outcome.
Execution will remain particularly important in ophthalmic surgery, where hospitals and surgeons evaluate device performance, clinical outcomes, procurement costs and procedural efficiency before adopting new technologies. The premium intraocular lens portfolio contributed to recent growth, but future performance will depend on product availability, competition and continued demand. Commercial momentum in these established products does not automatically validate the company’s investigational pipeline or guarantee successful future launches.
The prescription pharmaceutical business presents different considerations involving reimbursement, physician adoption, patient access and marketing expenditure. MIEBO and XIIDRA contributed to recent sales growth, providing an established commercial foundation for continued investment in ophthalmology. The incoming leadership will need to balance those opportunities against debt servicing, operational efficiency and the broader financial objectives of both companies.
Why did Bausch + Lomb shares decline despite the anticipated earnings upgrade?
The early market reaction suggests that investors were not treating the expected guidance increase as sufficient to offset the uncertainty created by the executive transition. Reuters reported that Bausch + Lomb’s United States-listed shares declined more than 5% in early trading on October 12 following the announcement. The movement represents an intraday reaction rather than a verified closing-price performance figure.
The shares had closed at $17.30 on October 9, before the leadership announcement. The subsequent decline coincided with disclosure of Saunders’ departure, Appio’s interim appointment and the preliminary earnings update. Although the combination of developments likely influenced investor attention, the relative contribution of each factor cannot be established from the share-price movement alone.
The reaction is commercially understandable because the company had recently reported improving financial results under Saunders and reaffirmed its established growth strategy. His departure introduces questions about leadership continuity, the appointment of a permanent chief executive and the future relationship with the controlling shareholder. Nevertheless, there is no evidence in the October announcement that the company’s operating performance has deteriorated or that previously disclosed clinical and commercial programmes have been discontinued.
Bausch Health shareholders face a related but distinct set of considerations. The parent retains a controlling economic interest in Bausch + Lomb, and changes in the subsidiary’s perceived valuation could affect the market’s assessment of Bausch Health’s holdings. Investors will also evaluate the expected earnings improvement against the parent’s own pharmaceutical operations, financing obligations and debt-reduction priorities.
What will investors and healthcare industry observers watch in the October 28 earnings reports?
The October 28 third-quarter results will provide the first detailed financial assessment following the leadership change. Investors will be able to compare the revised adjusted EBITDA guidance with the July forecasts and determine whether the increase reflects stronger revenue, improved product mix, cost efficiencies or a combination of factors. The companies have not yet quantified the proposed increase, making the size of the revision an important part of the forthcoming disclosure.
For Bausch + Lomb, the performance of Vision Care, Surgical and Pharmaceuticals will help establish whether second-quarter growth continued into the second half. Particular attention will fall on profitability, operating cash flow and management’s expectations for the final quarter of 2026. Stronger earnings accompanied by sustainable cash generation would provide a more persuasive indication of operational progress than an isolated adjustment to non-GAAP guidance.
The leadership transition creates a separate set of questions concerning governance and strategy. The company has not identified a permanent successor to Saunders or disclosed a formal timetable for resolving Appio’s interim appointment. Subsequent announcements may clarify whether the dual chief executive arrangement is intended primarily to support leadership continuity or forms part of a broader corporate decision-making structure.
The ownership relationship between Bausch Health and Bausch + Lomb will remain relevant regardless of the immediate earnings outcome. The parent has retained its controlling stake more than four years after the eye-care company’s public listing, while the potential separation continues to depend on financial and other conditions. Appio’s simultaneous leadership of both businesses may bring greater coordination, but it does not resolve those conditions by itself.
Bausch + Lomb enters the transition with stronger reported revenue, improved adjusted profitability and a substantial ophthalmology portfolio, making the timing of Saunders’ departure notable. The expected increase in 2026 earnings guidance provides a favourable operating signal, although its magnitude and underlying drivers remain undisclosed. October 28 will offer the first measurable test of that momentum, while the longer-term significance of Appio’s appointment will depend on whether he preserves the company’s operating progress and clarifies its strategic direction within the Bausch Health group.
